文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗四年随访期间急性视力丧失的发生率和原因调查

INVESTIGATION OF INCIDENCE AND CAUSES OF ACUTE VISION LOSS DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING A FOUR-YEAR FOLLOW-UP.
PubMed 文献 · Retina · 2023-01-01

这项回顾性队列研究纳入76例初诊新生血管性年龄相关性黄斑变性患者(76只眼),完成4年随访,调查每次检查时发生3行及以上视力丧失的发生率、危险因素和结局。4年内30只眼(39.5%)发生急性视力丧失,基线最佳矫正视力较低和椭圆体带断裂是独立预测因素;多数患者(86.7%)至少一次恢复至丧失前水平,但最终最佳矫正视力差于未发生急性视力丧失组。

要点

  • 4年随访中30只眼(39.5%)发生急性视力丧失,多数患者(86.7%)至少一次恢复至丧失前水平。
  • 基线最佳矫正视力较低和椭圆体带断裂是视力丧失发生的独立预测因素。
  • 视网膜色素上皮撕裂仅见于第一年;发生视力丧失者最终最佳矫正视力差于未发生组。

核心结论

  • 约半数年龄相关性黄斑变性患者在4年随访期间尽管持续接受抗血管内皮生长因子治疗仍发生急性视力丧失。
  • 多数患者暂时恢复视力,但随后视觉结局更差。

研究设计与样本

  • 回顾性队列研究,纳入初诊新生血管性年龄相关性黄斑变性并完成4年随访的患者,分析76例患者76只眼。

主要发现

  • 4年内30只眼(39.5%)发生急性视力丧失。
  • 基线最佳矫正视力较低和椭圆体带断裂是视力丧失发生的独立预测因素。
  • 视力丧失的原因和时间各异,但视网膜色素上皮撕裂仅见于第一年。
  • 发生视力丧失的患者中86.7%至少一次恢复至丧失前视力水平。
  • 发生急性视力丧失组最终最佳矫正视力差于未发生组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence, risk factors, and outcomes of patients with age-related macular degeneration who experienced acute vision loss despite periodic injections of anti-vascular endothelial growth factor treatment for 4 years. METHODS: This retrospective cohort study included patients who were diagnosed with treatment-naive neovascular age-related macular degeneration and completed a 4-year follow-up. The incidence and risk factors for the occurrence of three or more lines of visual loss at every checkup were investigated. RESULTS: The analysis included 76 eyes of 76 patients. Acute vision loss occurred in 30 eyes (39.5%) over 4 years. Lower baseline best-corrected visual acuity and disrupted ellipsoid zone were independent predictors of vision loss occurrence. Although the causes and timing of visual acuity loss varied, retinal pigment epithelium tears were observed only in the first year. Most patients (86.7%) who experienced vision loss recovered their vision to pre-loss levels at least once; however, the final best-corrected visual acuity was worse than that in the group that did not experience acute vision loss. CONCLUSION: Approximately half of the patients with age-related macular degeneration experienced acute vision loss during a 4-year follow-up, despite continuous anti-vascular endothelial growth factor treatment. Most patients recovered from vision losses temporarily; however, they experienced worse visual outcomes subsequently.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Machida A, Oishi A, Tsuiki E, et al. INVESTIGATION OF INCIDENCE AND CAUSES OF ACUTE VISION LOSS DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING A FOUR-YEAR FOLLOW-UP. Retina. 2023. PMID: 36657167. doi:10.1097/IAE.0000000000003740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。